Progestogens in the treatment of secondary amenorrhea.
Secondary amenorrhea is usually the primary purpose for which manufacturers of new progestogens seek FDA approval. Standards for safe and efficacious treatment of this condition have evolved throughout the past two decades. Studies have evaluated a variety of patient populations, corresponding with the several definitions of secondary amenorrhea that may be found in the literature. Ongoing research seeks to expand the indications for progestogen therapy to include hormone replacement in perimenopausal and postmenopausal women.
Simon
J A
JA
Department of Obstetrics and Gynecology, George Washington University, 2021 K Street, Northwest, Suite 500, Washington, D.C. 20006, USA.
D000284:Administration, Oral; D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000568:Amenorrhea / Q000188:drug therapy* / Q000209:etiology; D004394:Dydrogesterone / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000494:pharmacology; D008875:Middle Aged; D017698:Postmenopause; D017697:Premenopause; D011374:Progesterone / Q000008:administration & dosage / Q000494:pharmacology*; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000494:pharmacology; D011372:Progestins / Q000494:pharmacology / Q000627:therapeutic use*
D045167:Progesterone Congeners; D011372:Progestins; D011374:Progesterone; D004394:Dydrogesterone; D017258:Medroxyprogesterone Acetate